ConductScience.org, home

Comparison · NCT04023526-c8e6b547

Cusatuzumab 10 mg/kg Plus Azacitidine vs Cusatuzumab 20 mg/kg Plus Azacitidine: Number of Participants With Anti-cusatuzumab Antibodies

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Cusatuzumab 10 mg/kg Plus Azacitidine vs Cusatuzumab 20 mg/kg Plus Azacitidine: Number of Participants With Anti-cusatuzumab Antibodies. Trial comparisons, record NCT04023526-c8e6b547. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04023526-c8e6b547

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1490.07410.277wilson
Risk in group 20.04350.0120.145wilson
Risk difference, group 1 minus group 20.105-0.02090.237newcombe hybrid score
Risk ratio, group 1 over group 23.430.75115.6log
Odds ratio, group 1 over group 23.850.75519.6log
Number needed to treat, for one more participant with the outcome on Cusatuzumab 10 mg/kg Plus Azacitidine than on Cusatuzumab 20 mg/kg Plus Azacitidine9.48from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Cusatuzumab 10 mg/kg Plus Azacitidine
Participants received azacitidine 75 milligram per meter square (mg/m\^2) subcutaneously (SC) or intravenously (IV) on Day 1 through Day 7 and cusatuzumab 10 milligram per kilogram (mg/kg) IV on Day 3 and Day 17 of each 28-day cycle.
747OG000
Group 2Cusatuzumab 20 mg/kg Plus AzacitidineParticipants received azacitidine 75 mg/m\^2 SC or IV on Day 1 through Day 7 and cusatuzumab 20 mg/kg IV on Day 3 and Day 17 of each 28-day cycle.246OG001

Outcome

Type
SECONDARY
Title
Number of Participants With Anti-cusatuzumab Antibodies
Description
Number of participants exhibiting anti-drug antibodies for cusatuzumab.
Time frame
Up to 3 years and 5 months
Population
Participants with evaluable samples.

Source ClinicalTrials.gov

Trial

Title
A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
NCT number
NCT04023526
Phases
PHASE2
Conditions
Leukemia, Myeloid, Acute
Interventions
Azacitidine, Cusatuzumab
Lead sponsor
OncoVerity, Inc.
Results first posted
2024-07-30

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04023526-c8e6b547